Search

Your search keyword '"Andes, D."' showing total 353 results
Start Over Author "Andes, D."
353 results on '"Andes, D."'

1. Prospective multicenter international surveillance of Azole resistance in Aspergillus Fumigatus

Author

van der Linden, J.W.M., Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekotter, A., Lass-Florl, C., Klimko, N., Moore, C.B., Denning, D.W., Pasqualotto, A.C., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., and Verweij, P.E.

Subjects
Drug resistance in microorganisms -- Health aspects -- Research, Azoles (Class of compounds) -- Usage -- Health aspects, Aspergillosis -- Causes of -- Genetic aspects -- Drug therapy -- Research, Health
Abstract

Azole resistance is increasingly recognized as a problem in aspergillus diseases (1). Within the Aspergillus fumigatus species complex, new sibling species have been reported to cause invasive aspergillosis; these species [...]

Published
2015
Full Text
View/download PDF

5. The role of new posaconazole formulations in the treatment of candida albicans infections: Data from an in vitro Pharmacokinetic-Pharmacodynamic Model

Author

Beredaki, M.-I. Arendrup, M.C. Andes, D. Mouton, J.W. Meletiadis, J.

Abstract

Posaconazole is more active than fluconazole against Candida albicans in vitro and is approved for the treatment of oropharyngeal candidiasis but not for that of invasive candidiasis (IC). Here, we explored the efficacy of posaconazole against C. albicans in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model of IC and determined the probability of pharmacodynamic target attainment for the oral solution and intravenous (i.v.)/tablet formulations. Three clinical C. albicans isolates (posaconazole MICs, 0.008 to 0.25 mg/liter) were studied in the in vitro PK/PD dilution model simulating steady-state posaconazole PK. The in vitro exposure-effect relationship, area under the 24-h free drug concentration curve (fAUC0-24)/MIC, was described and compared with in vivo outcome in animals with IC. PK/PD susceptibility breakpoints and trough levels required for optimal treatment were determined for EUCAST and CLSI 24-h/48-h (CLSI24h/CLSI48h) methods using the fAUC0-24/MIC associated with half-maximal activity (EI50) and Monte Carlo simulation analysis for oral solution (400mg every 12 hours [q12h]) and i.v./tablet formulations (300mg q24h). The in vitro mean (95% confidence interval [CI]) EI50 was 330 (183 to 597) fAUC0-24/MIC for CLSI24h and 169 (92 to 310) for EUCAST/CLSI48h methods, which are close to the near-stasis in vivo effect. The probability of target attainment for EI50was estimated; for the wild-type isolates (MIC≤0.06 mg/liter), it was low for the oral solution and higher than 95% for the i.v./tablet formulations for the EUCAST/CLSI48h methods but not for the CLSI 24-h method. Non-wild-type isolates with EUCAST/ CLSI48h MICs of 0.125 and 0.25 mg/liter would require trough levels of >1.2 and >2.4 mg/liter, respectively. Posaconazole i.v./tablet formulations may have a role in the therapy of invasive infections by wild-type C. albicans isolates, provided that a steady state is reached quickly. A PK/PD susceptibility breakpoint at the epidemiological cutoff (ECV/ECOFF) of 0.06 mg/liter was determined. © 2021 American Society for Microbiology. All rights reserved.

Published
2021

7. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET)

Author

Kauffman, C. A., Freifeld, A. G., Andes, D. R., Baddley, J. W., Herwaldt, L., Walker, R. C., Alexander, B. D., Anaissie, E. J., Benedict, K., Ito, J. I., Knapp, K. M., Lyon, G. M., Marr, K. A., Morrison, V. A., Park, B. J., Patterson, T. F., Schuster, M. G., Chiller, T. M., and Pappas, P. G.

Published
2014
Full Text
View/download PDF

9. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., Groll, A.H., Sorrell, T.C., Bassetti, M., Akan, H., Alexander, B.D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R.W., Bretagne, S., Calandra, T., Caliendo, A.M., Castagnola, E., Cruciani, M., Cuenca-Estrella, M., Decker, C.F., Desai, S.R., Fisher, B., Harrison, T., Heussel, C.P., Jensen, H.E., Kibbler, C.C., Kontoyiannis, D.P., Kullberg, B.J., Lagrou, K., Lamoth, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Marr, K.A., Masur, H., Meis, J.F.G.M., Morrisey, C.O., Nucci, M., Ostrosky-Zeichner, L., Pagano, L., Patterson, T.F., Perfect, J.R., Racil, Z., Roilides, E., Ruhnke, M., Schaefer-Prokop, C.M., Shoham, S., Slavin, M.A., Stevens, David A., Thompson, G.R., Vazquez, J.A., Viscoli, C., Walsh, T.J., Warris, A., Wheat, L.J., White, P.L., Zaoutis, T.E., Pappas, P.G., Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., Groll, A.H., Sorrell, T.C., Bassetti, M., Akan, H., Alexander, B.D., Andes, D., Azoulay, E., Bialek, R., Bradsher, R.W., Bretagne, S., Calandra, T., Caliendo, A.M., Castagnola, E., Cruciani, M., Cuenca-Estrella, M., Decker, C.F., Desai, S.R., Fisher, B., Harrison, T., Heussel, C.P., Jensen, H.E., Kibbler, C.C., Kontoyiannis, D.P., Kullberg, B.J., Lagrou, K., Lamoth, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Marr, K.A., Masur, H., Meis, J.F.G.M., Morrisey, C.O., Nucci, M., Ostrosky-Zeichner, L., Pagano, L., Patterson, T.F., Perfect, J.R., Racil, Z., Roilides, E., Ruhnke, M., Schaefer-Prokop, C.M., Shoham, S., Slavin, M.A., Stevens, David A., Thompson, G.R., Vazquez, J.A., Viscoli, C., Walsh, T.J., Warris, A., Wheat, L.J., White, P.L., Zaoutis, T.E., and Pappas, P.G.

Abstract

Contains fulltext : 225781.pdf (Publisher’s version ) (Open Access), BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

10. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, JP, Chen, SC, Kauffman, CA, Steinbach, WJ, Baddley, JW, Verweij, PE, Clancy, CJ, Wingard, JR, Lockhart, SR, Groll, AH, Sorrell, TC, Bassetti, M, Akan, H, Alexander, BD, Andes, D, Azoulay, E, Bialek, R, Bradsher, RW, Bretagne, S, Calandra, T, Caliendo, AM, Castagnola, E, Cruciani, M, Cuenca-Estrella, M, Decker, CF, Desai, SR, Fisher, B, Harrison, T, Heussel, CP, Jensen, HE, Kibbler, CC, Kontoyiannis, DP, Kullberg, B-J, Lagrou, K, Lamoth, F, Lehrnbecher, T, Loeffler, J, Lortholary, O, Maertens, J, Marchetti, O, Marr, KA, Masur, H, Meis, JF, Morrisey, CO, Nucci, M, Ostrosky-Zeichner, L, Pagano, L, Patterson, TF, Perfect, JR, Racil, Z, Roilides, E, Ruhnke, M, Prokop, CS, Shoham, S, Slavin, MA, Stevens, DA, Thompson, GR, Vazquez, JA, Viscoli, C, Walsh, TJ, Warris, A, Wheat, LJ, White, PL, Zaoutis, TE, Pappas, PG, Donnelly, JP, Chen, SC, Kauffman, CA, Steinbach, WJ, Baddley, JW, Verweij, PE, Clancy, CJ, Wingard, JR, Lockhart, SR, Groll, AH, Sorrell, TC, Bassetti, M, Akan, H, Alexander, BD, Andes, D, Azoulay, E, Bialek, R, Bradsher, RW, Bretagne, S, Calandra, T, Caliendo, AM, Castagnola, E, Cruciani, M, Cuenca-Estrella, M, Decker, CF, Desai, SR, Fisher, B, Harrison, T, Heussel, CP, Jensen, HE, Kibbler, CC, Kontoyiannis, DP, Kullberg, B-J, Lagrou, K, Lamoth, F, Lehrnbecher, T, Loeffler, J, Lortholary, O, Maertens, J, Marchetti, O, Marr, KA, Masur, H, Meis, JF, Morrisey, CO, Nucci, M, Ostrosky-Zeichner, L, Pagano, L, Patterson, TF, Perfect, JR, Racil, Z, Roilides, E, Ruhnke, M, Prokop, CS, Shoham, S, Slavin, MA, Stevens, DA, Thompson, GR, Vazquez, JA, Viscoli, C, Walsh, TJ, Warris, A, Wheat, LJ, White, PL, Zaoutis, TE, and Pappas, PG

Abstract

BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

25. Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi

Author

Desai, A.V. (Amit V.), Kovanda, L.L. (Laura L.), Hope, W.W. (William W.), Andes, D., Mouton, J.W. (Johan), Kowalski, D.L. (Donna L.), Townsend, R.W. (Robert W.), Mujais, S. (Salim), Bonate, P.L. (Peter L.), Desai, A.V. (Amit V.), Kovanda, L.L. (Laura L.), Hope, W.W. (William W.), Andes, D., Mouton, J.W. (Johan), Kowalski, D.L. (Donna L.), Townsend, R.W. (Robert W.), Mujais, S. (Salim), and Bonate, P.L. (Peter L.)

Abstract

Isavuconazole, the active moiety of the water-soluble prodrug isavuconazonium sulfate, is a triazole antifungal agent for the treatment of invasive fungal infections. The purpose of this analysis was to characterize the isavuconazole exposure-response relationship for measures of efficacy and safety in patients with invasive aspergillosis and infections by other filamentous fungi from the SECURE clinical trial. Two hundred thirty-one patients who received the clinical dosing regimen and had exposure parameters were included in the analysis. The primary drug exposure parameters included were predicted trough steady-state plasma concentrations, predicted trough concentrations after 7 and 14 days of drug administration, and area under the curve estimated at steady state (AUCss). The exposure parameters were analyzed against efficacy endpoints that included all-cause mortality through day 42 in the intent-to-treat (ITT) and modified ITT populations, data review committee (DRC)-adjudicated overall response at end of treatment (EOT)

Published
2017
Full Text
View/download PDF

27. Dual action antifungal small molecule modulates multidrug efflux and TOR signaling

Author

Shekhar Guturja, T, Gunaherath, G, Wijeratne, E, Lambert, J, Averette, A, Lee, S, Kim, T, Bahn, Y, Tripodi, F, Ammar, R, Döhl, K, Niewola Staszkowska, K, Schmitt, L, Loewith, R, Proth, F, Sanglard, D, Andes, D, Nislow, C, Coccetti, P, Gingras, A, Heitman, J, Gunatilaka, A, Ecowen, L, Ecowen, L., TRIPODI, FARIDA, COCCETTI, PAOLA, Shekhar Guturja, T, Gunaherath, G, Wijeratne, E, Lambert, J, Averette, A, Lee, S, Kim, T, Bahn, Y, Tripodi, F, Ammar, R, Döhl, K, Niewola Staszkowska, K, Schmitt, L, Loewith, R, Proth, F, Sanglard, D, Andes, D, Nislow, C, Coccetti, P, Gingras, A, Heitman, J, Gunatilaka, A, Ecowen, L, Ecowen, L., TRIPODI, FARIDA, and COCCETTI, PAOLA

Abstract

There is an urgent need for new strategies to treat invasive fungal infections, which are a leading cause of human mortality. Here, we establish two activities of the natural product beauvericin, which potentiates the activity of the most widely deployed class of antifungal against the leading human fungal pathogens, blocks the emergence of drug resistance, and renders antifungal-resistant pathogens responsive to treatment in mammalian infection models. Harnessing genome sequencing of beauvericin-resistant mutants, affinity purification of a biotinylated beauvericin analog, and biochemical and genetic assays reveals that beauvericin blocks multidrug efflux and inhibits the global regulator TORC1 kinase, thereby activating the protein kinase CK2 and inhibiting the molecular chaperone Hsp90. Substitutions in the multidrug transporter Pdr5 that enable beauvericin efflux impair antifungal efflux, thereby impeding resistance to the drug combination. Thus, dual targeting of multidrug efflux and TOR signaling provides a powerful, broadly effective therapeutic strategy for treating fungal infectious disease that evades resistance.

Published
2016

30. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus.

Author

Linden, J.W.M. van der, Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C.B., Denning, D., Pasqualotto, A., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., Verweij, P.E., Linden, J.W.M. van der, Arendrup, M.C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P.M., Chryssanthou, E., Mellado, E., Kidd, S.E., Tortorano, A.M., Dannaoui, E., Gaustad, P., Baddley, J.W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C.B., Denning, D., Pasqualotto, A., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W.J.G., and Verweij, P.E.

Abstract

Contains fulltext : 153751.pdf (publisher's version ) (Open Access)

Published
2015

31. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

Author

Verweij, P.E., Ananda-Rajah, M., Andes, D., Arendrup, M.C., Bruggemann, R.J.M., Chowdhary, A., Cornely, O.A., Denning, D.W., Groll, A.H., Izumikawa, K., Kullberg, B.J., Lagrou, K., Maertens, J., Meis, J.F.G.M., Newton, P., Page, I., Seyedmousavi, S., Sheppard, D.C., Viscoli, C., Warris, A., Donnelly, J.P., Verweij, P.E., Ananda-Rajah, M., Andes, D., Arendrup, M.C., Bruggemann, R.J.M., Chowdhary, A., Cornely, O.A., Denning, D.W., Groll, A.H., Izumikawa, K., Kullberg, B.J., Lagrou, K., Maertens, J., Meis, J.F.G.M., Newton, P., Page, I., Seyedmousavi, S., Sheppard, D.C., Viscoli, C., Warris, A., and Donnelly, J.P.

Abstract

Contains fulltext : 153203.pdf (Publisher’s version ) (Open Access)

Published
2015

34. Prospective Multicenter International Surveillance of Azole Resistance inAspergillus fumigatus

Author

van der Linden, J.W.M., primary, Arendrup, M.C., additional, Warris, A., additional, Lagrou, K., additional, Pelloux, H., additional, Hauser, P.M., additional, Chryssanthou, E., additional, Mellado, E., additional, Kidd, S.E., additional, Tortorano, A.M., additional, Dannaoui, E., additional, Gaustad, P., additional, Baddley, J.W., additional, Uekötter, A., additional, Lass-Flörl, C., additional, Klimko, N., additional, Moore, C.B., additional, Denning, D.W., additional, Pasqualotto, A.C., additional, Kibbler, C., additional, Arikan-Akdagli, S., additional, Andes, D., additional, Meletiadis, J., additional, Naumiuk, L., additional, Nucci, M., additional, Melchers, W.J.G., additional, and Verweij, P.E., additional

Published
2015
Full Text
View/download PDF

35. Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network

Author

Balajee S.A., Kano R., Baddley J.W., Moser S.A., Marr K.A., Alexander B.D., Andes D., Kontoyiannis D.P., Perrone G., Peterson S., Brandt M.E., Pappas P.G., and Chiller T.

Abstract

A large aggregate collection of clinical isolates of aspergilli (n=218) from transplant patients with proven or probable invasive aspergillosis was available from the Transplant-Associated Infection Surveillance Network, a 6-year prospective surveillance study. To determine the Aspergillus species distribution in this collection, isolates were subjected to comparative sequence analyses by use of the internal transcribed spacer and beta-tubulin regions. Aspergillus fumigatus was the predominant species recovered, followed by A. flavus and A. niger. Several newly described species were identified, including A. lentulus and A. calidoustus; both species had high in vitro MICs to multiple antifungal drugs. Aspergillus tubingensis, a member of the A. niger species complex, is described from clinical specimens; all A. tubingensis isolates had low in vitro MICs to antifungal drugs.

Published
2009

36. Clinical Research In The Lay Press: Irresponsible Journalism Raises A Huge Dose Of Doubt

Author

Anaissie, E.J, Segal, B.H, Graybill, J.R, Arndt, C, Perfect, J.R, Kleinberg, M, Pappas, P, Benjamin, D, Rubin, R, Aberg, J.A, Adderson, E.E, Adler-Shohet, F.C, Akan, H, Akova, M, Almyroudis, N.G, Alexander, B.D, Andes, D, Arrieta, A, Baddley, J.W, Barron, M.A, Belzberg, H, Boucher, H.W, Boyce, T.G, Casadevall, A, Chandrasekar, P.H, Cleary, J.D, Cordonnier, C, Cornely, O.A, Cuenca-Estrella, M, Daly, J.S, Daoura, N, Denning, D.W, DePauw, B, De Repentigny, L, Dignani, M.C, Dismukes, W.E, Donnelly, J.P, Donowitz, G.R, Dupont, B, Drusano, G, Ellis, M, Espinel-Ingroff, A, Fishman, J.A, Fleming, R, Forrest, G, Ghannoum, M, Goldman, M, Grazziutti, M, Greene, J.H, Greenberg, R.N, Gubbins, P.O, Hadley, S, Herbrecht, R, Hiemenz, J.W, Hope, W, Hospenthal, D.R, Husain, S, Ito, J.I, Jacobson, R.M, Johnson, M, Keating, M.R, Kett, D.H, Knapp, K, Kontoyiannis, D.P, Krcmery, V.C, Larsen, R, Laverdiere, M, Ljungman, P, Lortholary, O, Maertens, J, Marriott, D, Mattiuzzi, G, McGinnis, M.R, Morris, M, Nucci, M, Odds, F.C, Pankey, G.A, Patterson, T, Pfaller, M, Razonable, R.R, Reboli, A.C, Rinaldi, M.G, Roberts, G.D, Rodriguez Tudela, J.L, Rotstein, C, Ruhnke, M, Schuster, M, Shoham, S, Sia, I.G, Siebel, N, Silviera, F, Singh, N, Sobel, J, Solomkin, J.S, Sorrell, T.C, Steinbach, W.J, Temesgen, Z, Tortorano, A, Vartivarian, S, Verweij, P, Viscoli, C, Viviani, M.A, Walker, R.C, Wheat, J.L, Wiley, J, Williamson, P, Wingard, J.R, Yu, V.L, Zaoutis, T., and İç Hastalıkları

Published
2006

37. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt

Author

Anaissie, Ej, Segal, Bh, Graybill, Jr, Arndt, C, Perfect, Jr, Kleinberg, M, Pappas, P, Benjamin, D, Rubin, R, Aberg, Ja, Adderson, Ee, ADLER SHOHET FC, Akan, H, Akova, M, Almyroudis, Ng, Alexander, Bd, Andes, D, Arrieta, A, Baddley, Jw, Barron, Ma, Belzberg, H, Boucher, Hw, Boyce, Tg, Casadevall, A, Chandrasekar, Ph, Cleary, Jd, Cordonnier, C, Corneli, Oa, CUENCA ESTRELLA, M, Daly, Js, Daoura, N, Denning, Dw, Depauw, B, DE REPENTIGNY, L, Dignani, Mc, Dismukes, Wf, Donnelly, Jp, Donowitz, Gr, Dupont, B, DRUSANO GM ELLIS, M, ESPINEL INGRFF, A, Fishman, Ja, Fleming, R, Forrest, G, Ghannoum, M, Goldman, M, Grazziutti, M, Greene, Jn, Greenberg, Rn, Gubbin, Po, Hadley, S, Herbrecht, R, Hiemenez, Jw, Hope, W, Hopenthal, Dr, Husain, S, Ito, Ji, Jaconson, Rm, Johnson, M, Keating, Mr, Kett, Dh, Knapp, K, Kontoyannis, Dp, Krcmery, Vc, Larsen, R, Laverdiere, M, Ljungman, P, Lortholary, O, Maertens, J, Marriott, D, Mattiuzzi, G, Mcginnins, Mr, Morris, M, Nucci, M, Odds, Fc, Pankey, Ga, Patterson, T, Pfaller, M, Razonable, Rr, Reboli, Ac, Rinaldi, Mg, Roberts, Gd, RODRIGUEZ TUDELA JL, Rotstein, C, Ruhnke, M, Schuster, M, Shoham, S, Sia, Ig, Siebel, N, Silviera, F, Singh, N, Sobel, J, Solomkin, Js, Sorrell, Tc, Steinbach, Wj, Temesgen, Z, Tortorano, A, Vartivarian, S, Verveij, P, Viscoli, Claudio, Viviani, Am, Walker, Rc, Wheat, Jl, Wiley, J, Williamson, P, Wingard, Jr, Yu, Vl, and Zaoutis, T.

Published
2006

42. Reply to Anaissie and Nucci and to Cisneros et al.

Author

Andes, D., Safdar, N., Baddley, J.W., Kullberg, B.J., Pappas, P.G., Andes, D., Safdar, N., Baddley, J.W., Kullberg, B.J., and Pappas, P.G.

Abstract

Item does not contain fulltext

Published
2012

43. Protein binding: do we ever learn?

Author

Zeitlinger, M.A., Derendorf, H., Mouton †, J.W., Cars, O., Craig, W.A., Andes, D., Theuretzbacher, U., Zeitlinger, M.A., Derendorf, H., Mouton †, J.W., Cars, O., Craig, W.A., Andes, D., and Theuretzbacher, U.

Abstract

Item does not contain fulltext, Although the influence of protein binding (PB) on antibacterial activity has been reported for many antibiotics and over many years, there is currently no standardization for pharmacodynamic models that account for the impact of protein binding of antimicrobial agents in vitro. This might explain the somewhat contradictory results obtained from different studies. Simple in vitro models which compare the MIC obtained in protein-free standard medium versus a protein-rich medium are prone to methodological pitfalls and may lead to flawed conclusions. Within in vitro test systems, a range of test conditions, including source of protein, concentration of the tested antibiotic, temperature, pH, electrolytes, and supplements may influence the impact of protein binding. As new antibiotics with a high degree of protein binding are in clinical development, attention and action directed toward the optimization and standardization of testing the impact of protein binding on the activity of antibiotics in vitro become even more urgent. In addition, the quantitative relationship between the effects of protein binding in vitro and in vivo needs to be established, since the physiological conditions differ. General recommendations for testing the impact of protein binding in vitro are suggested.

Published
2011

45. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Author

Pappas, P.G., Kauffman, C.A., Andes, D., Benjamin Jr., D.K., Calandra, T, Edwards, J.E., Filler, S.G., Fisher, J.F., Kullberg, B.J., Ostrosky-Zeichner, L., Reboli, A.C., Rex, J.H., Walsh, T.J., Sobel, J.D., Pappas, P.G., Kauffman, C.A., Andes, D., Benjamin Jr., D.K., Calandra, T, Edwards, J.E., Filler, S.G., Fisher, J.F., Kullberg, B.J., Ostrosky-Zeichner, L., Reboli, A.C., Rex, J.H., Walsh, T.J., and Sobel, J.D.

Abstract

Contains fulltext : 79640.pdf (publisher's version ) (Closed access), Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. Since 2004, several new antifungal agents have become available, and several new studies have been published relating to the treatment of candidemia, other forms of invasive candidiasis, and mucosal disease, including oropharyngeal and esophageal candidiasis. There are also recent prospective data on the prevention of invasive candidiasis in high-risk neonates and adults and on the empiric treatment of suspected invasive candidiasis in adults. This new information is incorporated into this revised document.

Published
2009

46. Histoplasmosis After Solid Organ Transplant

Author

Assi, M., primary, Martin, S., additional, Wheat, L. J., additional, Hage, C., additional, Freifeld, A., additional, Avery, R., additional, Baddley, J. W., additional, Vergidis, P., additional, Miller, R., additional, Andes, D., additional, Young, J.-A. H., additional, Hammoud, K., additional, Huprikar, S., additional, McKinsey, D., additional, Myint, T., additional, Garcia-Diaz, J., additional, Esguerra, E., additional, Kwak, E. J., additional, Morris, M., additional, Mullane, K. M., additional, Prakash, V., additional, Burdette, S. D., additional, Sandid, M., additional, Dickter, J., additional, Ostrander, D., additional, Antoun, S. A., additional, and Kaul, D. R., additional

Published
2013
Full Text
View/download PDF

50. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.

Author

Anaissie, E., Segal, B.H., Graybill, J.R., Arndt, C., Perfect, J.R., Kleinberg, M., Pappas, P.G., Benjamin, D., Rubin, R., Aberg, J.A., Adderson, E.E., Adler-Shohet, F.C., Akan, H., Akova, M., Almyroudis, N.G., Alexander, B.D., Andes, D., Arrieta, A., Baddley, J.W., Barron, M.A., Belzberg, H., Boucher, H.W., Boyce, T.G., Casadevall, A., Chandrasekar, P.H., Cleary, J.D., Cordonnier, C., Cornely, O.A., Cuenca-Estrella, M., Daly, J.S., Daoura, N., Denning, D.W., Pauw, B.E. de, Repentigny, L. de, Dignani, M.C., Dismukes, W.E., Donnelly, J.P., Donowitz, G., Dupont, B., Drusano, G., Ellis, M., Espinel-Ingroff, A., Fishman, J.A., Fleming, R., Forrest, G., Ghannoum, M.A., Goldman, M, Grazziutti, M., Greene, J.N., Greenberg, R.N., Gubbins, P.O., Hadley, S., Herbrecht, R., Hiemenz, J.W., Hope, W., Hospenthal, D.R., Husain, S., Ito, J.I., Jacobson, R.M., Johnson, M., Keating, M.R., Kett, D.H., Knapp, K., Kontoyiannis, D.P., Krcmery, V., Larsen, R., Laverdiere, M., Ljungman, P., Lortholary, O., Maertens, J., Marriott, D., Mattiuzzi, G., McGinnis, M.R., Morris, M., Nucci, M., Odds, F.C., Pankey, G.A., Patterson, T., Pfaller, M., Razonable, R.R., Reboli, A.C., Rinaldi, M.G., Roberts, G.D., Rodriguez-Tudela, J.L., Rotstein, C., Ruhnke, M., Schuster, M., Shoham, S., Sia, I.G., Siebel, N., Silviera, F, Singh, N., Sobel, J., Solomkin, J.S., Sorrell, T.C., Steinbach, W.J., Temesgen, Z., Tortorano, A., Vartivarian, S., Anaissie, E., Segal, B.H., Graybill, J.R., Arndt, C., Perfect, J.R., Kleinberg, M., Pappas, P.G., Benjamin, D., Rubin, R., Aberg, J.A., Adderson, E.E., Adler-Shohet, F.C., Akan, H., Akova, M., Almyroudis, N.G., Alexander, B.D., Andes, D., Arrieta, A., Baddley, J.W., Barron, M.A., Belzberg, H., Boucher, H.W., Boyce, T.G., Casadevall, A., Chandrasekar, P.H., Cleary, J.D., Cordonnier, C., Cornely, O.A., Cuenca-Estrella, M., Daly, J.S., Daoura, N., Denning, D.W., Pauw, B.E. de, Repentigny, L. de, Dignani, M.C., Dismukes, W.E., Donnelly, J.P., Donowitz, G., Dupont, B., Drusano, G., Ellis, M., Espinel-Ingroff, A., Fishman, J.A., Fleming, R., Forrest, G., Ghannoum, M.A., Goldman, M, Grazziutti, M., Greene, J.N., Greenberg, R.N., Gubbins, P.O., Hadley, S., Herbrecht, R., Hiemenz, J.W., Hope, W., Hospenthal, D.R., Husain, S., Ito, J.I., Jacobson, R.M., Johnson, M., Keating, M.R., Kett, D.H., Knapp, K., Kontoyiannis, D.P., Krcmery, V., Larsen, R., Laverdiere, M., Ljungman, P., Lortholary, O., Maertens, J., Marriott, D., Mattiuzzi, G., McGinnis, M.R., Morris, M., Nucci, M., Odds, F.C., Pankey, G.A., Patterson, T., Pfaller, M., Razonable, R.R., Reboli, A.C., Rinaldi, M.G., Roberts, G.D., Rodriguez-Tudela, J.L., Rotstein, C., Ruhnke, M., Schuster, M., Shoham, S., Sia, I.G., Siebel, N., Silviera, F, Singh, N., Sobel, J., Solomkin, J.S., Sorrell, T.C., Steinbach, W.J., Temesgen, Z., Tortorano, A., and Vartivarian, S.

Abstract

Contains fulltext : 50792.pdf (publisher's version ) (Open Access)

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results